Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

NCT ID: NCT04440527

Last Updated: 2020-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-22

Study Completion Date

2024-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, randomized, monocentric, part blinded, controlled non-inferiority study of glaucoma patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma Pseudoexfoliation Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microshunt

Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).

Group Type EXPERIMENTAL

Preserflo / Innfocus Microshunt

Intervention Type DEVICE

The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.

Trabeculectomy

Patients will be treated with trabeculectomy.

Group Type ACTIVE_COMPARATOR

Trabeculectomy

Intervention Type OTHER

Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Preserflo / Innfocus Microshunt

The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.

Intervention Type DEVICE

Trabeculectomy

Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Primary open angle glaucoma or pseudoexfoliation glaucoma
* medically uncontrollable intraocular pressure or intolerance of topical therapy
* negative urine/serum pregnancy test of women in childbearing age
* signed and dated informed consent

Exclusion Criteria

* previous incisional glaucoma procedure on affected eye
* pregnancy, nursing period
* Patients in military service, training periods and civil service
* Participation in another clinical trail
* pre-existing ocular pathologies: high myopia (refraction ≥8.00 D), thin conjunctiva
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University Innsbruck

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Teresa Rauchegger, Dr.

Role: CONTACT

+43 512 504 24184

Barbara Teuchner, Dr.

Role: CONTACT

+43 512 504 24184

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAINT-Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.